Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.44 |
| ▸ | PPARG | P37231 | 13/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929162 | 1.00 | PPARA (0.44) | PPARAPPARGPPARDNPSR1MAPT | |
| SCHEMBL1929449 | 0.92 | PPARA (0.39) | PPARAPPARGPPARDNPSR1 | |
| SCHEMBL1928923 | 0.92 | PPARA (0.42) | PPARAPPARGPPARD | |
| SCHEMBL1928459 | 0.92 | PPARA (0.39) | PPARAPPARGPPARDNPSR1 | |
| SCHEMBL1928457 | 0.92 | PPARA (0.39) | PPARAPPARGPPARDNPSR1 | |
| SCHEMBL1928921 | 0.92 | PPARA (0.42) | PPARAPPARGPPARD | |
| SCHEMBL3975231 | 0.91 | PPARA (0.45) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL3975385 | 0.91 | PPARA (0.45) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL3981698 | 0.91 | PPARA (0.45) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL3975389 | 0.91 | PPARA (0.45) | PPARAPPARGPPARDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956077-B2 | 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-7956077-B2 | 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-7956077-B2 | 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| EP-1778655-B1 | 2 - { - 3 2 - (PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDS (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197613-A1 | 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.